Compare Sibanye Stillwater Ltd (SBSW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Twist Bioscience Corp — how do they compare? Sibanye Stillwater Ltd trades at $10.01 (market cap $6.88B), while Twist Bioscience Corp trades at $160.26 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and Twist Bioscience Corp for 27 Days on average.
| SBSW | TWST | |
|---|---|---|
Market Cap | $6.88B | $10.08B |
Volume | 4,474,536 | 4,229,037 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $205.00 |
52-Week Low | $8.00 | $25.45 |
Typical Hold Time | 51 Days | 27 Days |
Enterprise Value | $7.78B | $10.01B |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $9.68, down 3.3% today, amid a bearish technical outlook. The stock shows mixed earnings with a recent Q2 2026 beat but a Q4 2025 miss. Fundamentals reflect strong revenue growth projected to $164.9B in 2026 and attractive valuation ratios, including a P/E of 8.12 and EV/EBITDA of 4.09, though net income was negative in 2025. Cash flow trends improved significantly in 2025, turning net positive. Analyst sentiment is moderately bullish with a $14.25 consensus target.
The outlook hinges on execution of its growth roadmap and commodity price stability. Upside potential exists from operational momentum and disciplined capital allocation, but risks include debt levels, volatile earnings, and macroeconomic pressures on mining sectors. The stock presents a value opportunity if profitability rebounds as projected.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
